What happened
Quince Therapeutics, Inc. (NASDAQ: QNCX) said it changed its name to IRulya Therapeutics Inc. effective at 4:01 p.m. Eastern Time on October 9, 2026.
The common stock is expected to begin trading on the Nasdaq Capital Market under IRLA on October 12, 2026.
John Militello, CPA, became chief financial officer and Keith R. Fandrick, Ph.D., became chief operating officer on the same day.
Dirk Thye, M.D., and Brendan Hannah resigned from their roles, the filing says.
The board added Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise.
The name change follows Quince's previously announced merger with privately held Orphai Therapeutics and a concurrent private placement of about $115 million in upfront gross proceeds in May 2026.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Cash balance as of June 30, 2026 | $116 million | Exhibit 99.1 press release | |
| Concurrent private placement gross proceeds | approximately $115 million | Exhibit 99.1 press release | |
| Expected common stock outstanding after conversion | approximately 10,841,470 shares | SEC 8-K |
Read more: Quince Therapeutics (QNCX) stock analysis and investment case
Why it matters
The filing says cash and cash equivalents were $116 million as of June 30, 2026 and expects that amount to fund operations through the end of 2028.
It also points to expected Phase 2 readouts for LAM-001 in BOS, PH-ILD and SAPH.
OptimistFi's case is that Quince needs a financable clinical or regulatory win before dilution erodes upside.
This filing is mixed for that view because it pairs $116 million of cash and about $115 million in gross proceeds with future Phase 2 readouts that still have to land.
OptimistFi's ratio puts the roughly $115 million private placement at about 99.1% of that cash balance.
LAM-001 remains investigational, so the filing still depends on future data readouts rather than a proven product.
Browse: stock research on every company OptimistFi covers
What's next
Stockholders approved the issuance of common stock from the Series C preferred stock and warrants on October 6, 2026.
The preferred stock is set to convert at 5:00 p.m. ET on October 9, 2026.
The company expects outstanding common stock to be about 10,841,470 after that conversion.
The company plans to start a Phase 2 study in SAPH in 4Q26.
It expects BOS data in the first quarter of 2027 and PH-ILD data in the first quarter of 2028.
Those readouts will show whether the financing and name change lead to a clinical payoff.
More from OptimistFi
- QNCX stock: the Quince Therapeutics thesis, its status and the next test to watch
- Prudential Financial, Inc. (NYSE: PRU) Faces Longer Japan Sales Ban
- Humana Inc. (NYSE: HUM) Lifts Bonus-Eligible Medicare Coverage to 95%
- NVIDIA Corporation (NASDAQ: NVDA) Commits $1 Billion to US Science
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- Exhibit 99.1 press release — Press release furnished with the Form 8-K on October 9, 2026.
- Form 8-K — Current report filed with the SEC on October 7, 2026.
Read the full OptimistFi thesis on Quince Therapeutics, Inc.: https://optimistfi.com/stocks/QNCX
See what would break the Quince Therapeutics, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Quince Therapeutics, Inc. investment case, its status and the next test to watch live on the Quince Therapeutics, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
